These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 35928819)

  • 21. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
    Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Gao J; Dahiya S; Patel SA
    Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving therapy of DLBCL: Bispecific antibodies.
    Hutchings M
    Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
    N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Gordon MJ; Sureda A; Westin JR
    Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
    Shirouchi Y; Maruyama D
    Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
    Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Top advances in lymphoma for 2021.
    Patel DA; Kahl BS
    Cancer; 2022 Dec; 128(23):4047-4051. PubMed ID: 36201139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
    Dada R
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.
    Wang C; Liu Y
    J Hematol Oncol; 2023 Mar; 16(1):20. PubMed ID: 36895020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.